- Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has announced a partnership with LegoChem Biosciences for the development and manufacturing of an antibody-drug conjugate (ADC) program.
- The ADC program is designed to treat solid tumours, with LegoChem Biosciences aiming to submit an Investigational New Drug application to the U.S. FDA in the first half of 2025.
- Samsung Biologics is also on track to complete the construction of a dedicated ADC facility within 2024.
Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has entered into a strategic partnership with LegoChem Biosciences, a biotech company at the forefront of the research and development of antibody-drug conjugate (ADC) programs. This partnership was announced on February 7, 2024.
Under the terms of the agreement, Samsung Biologics will provide antibody development and drug substance manufacturing services as part of LegoChem Biosciences’ ADC program. This program is specifically designed to treat solid tumours.
LegoChem Biosciences aims to submit an Investigational New Drug application to the U.S. FDA in the first half of 2025. Non-clinical data has shown promising efficacy results.
“Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,” John Rim, Samsung Biologics’ CEO and president, said in the release. “We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”
This partnership is expected to secure a stable domestic supply chain for LegoChem Biosciences, which had previously sourced antibodies for ADC through overseas companies. Samsung Biologics will offer comprehensive services for ADC development and manufacturing, leveraging its expertise and capacity in antibody engineering, process development, and large-scale manufacturing of antibodies.
Overview of outsourcing trends 
